Indication
Low Grade Glioma of Brain With BRAF Aberration
1 clinical trial
3 products
Clinical trial
Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine (HCQ) for BRAF V600E-mutant or Trametinib and HCQ for BRAF Fusion/Duplication Positive or NF1-associated Recurrent or Progressive Gliomas in Children and Young AdultsStatus: Recruiting, Estimated PCD: 2026-08-30
Product
DabrafenibProduct
TrametinibProduct
Hydroxychloroquine